---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-003072"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2022-08-12T23:59:59+00:00"
generated_at: "2026-06-24T00:19:52.327029+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Chemomab Q2 net loss $6.2M, cash $51.8M; NASH topline due by year-end

## Summary
- Net loss $6.2M ($0.03/share) for Q2 2022 vs $2.8M loss in Q2 2021; R&D expense rose to $2.9M from $1.3M.
- Cash, equivalents and deposits $51.8M at June 30; runway expected through end of 2023.
- Phase 2 NASH trial completed treatment; topline safety and activity data expected before year-end 2022.
- Phase 2 PSC trial expanded to 93 patients across three dose cohorts; topline data anticipated H2 2024.
- Appointed Jill Quigley to board, Ilan Vaknin as VP R&D, and Christina Crater as VP Clinical Development.

## SEC filing metadata
- accession: 0001178913-22-003072
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2022-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891322003072/0001178913-22-003072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891322003072/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-003072
- JSON: https://secwatch.observer/filing/0001178913-22-003072.json
- Plain text: https://secwatch.observer/filing/0001178913-22-003072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.